


PHARMACEUTICAL 2023

MACROGENICS INC Rank 247 of 446









PHARMACEUTICAL 2023

MACROGENICS INC Rank 247 of 446



The relative strengths and weaknesses of MACROGENICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MACROGENICS INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 47% points. The greatest weakness of MACROGENICS INC is the variable Research and Development, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 59%, being 16% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	222,180
Cost of Goods Sold	3,351
Intangible Assets	0
Liabilities, Current	48,611
Liabilities, Non-Current	30,364
Other Assets	28,713
Other Compr. Net Income	56
Other Expenses	4,033
Other Liabilities	59,480
Other Net Income	1,660
Other Revenues	151,941
Property and Equipment	29,575
Research and Development	207,026
Selling, General and Administrative Expense	58,949

Output Variable	Value in 1000 USD
Assets	280,468
Liabilities	138,455
Expenses	273,359
Revenues	151,941
Stockholders Equity	142,013
Net Income	-119,758
Comprehensive Net Income	-119,730
Economic Capital Ratio	59%

